1. Introduction {#s0005}
===============

Despite recent decreases in cancer diagnoses in the western world, prostate cancer still accounts for approximately 1 in 5 new cancer diagnoses in men and remains one of the leading causes of death. It is estimated that about 164,000 new cases will develop and 29,000 men will die in 2018 in the United States alone due to prostate cancer[@bib1]. Worldwide, incidence rates continue to increase in the developing world, while rates in Asia remain the lowest of all major geographical regions[@bib2].

Typically, most patients diagnosed with prostate cancer are first treated through androgen deprivation therapy (ADT). While ADT has shown to be effective at first, the vast majority of patients develop resistance to this treatment, developing castration-resistant prostate cancer (CRPC) and other therapeutic options are required to treat the disease[@bib3], [@bib4], [@bib5], [@bib6]. Many times therapy involves the use of taxanes, microtubule stabilizing agents, which have shown to disrupt the G2/M-phase of cell cycle and induce apoptosis[@bib7], [@bib8], [@bib9]. Paclitaxel (PXL), its nanoformulation Abraxane, and docetaxel (DXL) are the three 1st line taxanes approved to treat cancer in this manner. DXL is the approved choice in treating prostate cancer due to its effectiveness at prolonging the lifespan of prostate cancer patients when used in combination with prednisone[@bib10]. Many problems still exist with these taxanes including development of resistance, high toxicity (especially neutropenia and peripheral neuropathy), and limited bioavailability[@bib11], [@bib12], [@bib13], [@bib14].

As such, efforts to tackle any or all of these issues have increased in recent years. In 2010 the U.S. Food and Drug Administration (FDA) approved a new taxane, cabazitaxel (CXL), for treatment of prostate cancer for those who have already been treated with DXL and developed resistance[@bib15]. Additionally, four other non taxane treatments have been approved in the last seven years. Abiraterone and enzalutamide inhibit androgen receptor (AR) function through biosynthesis inhibition and nuclear translocation respectively[@bib16], [@bib17]. Sipuleucel-T, the first vaccine approved for treatment of hormone refractory prostate cancer, has unknown exact mechanism of action but stimulates T-cell response against highly expressed antigen presenting cells[@bib18]. Lastly, Radium-223, an alpha particle emitter, has been approved for patients whose cancer has spread to the bones[@bib19].

With all of these treatments approved, prostate cancer patients have an exceptional number of options for therapy. Yet, prostate cancer is still one of the leading causes of death in men and more work is needed to understand the mechanism behind resistance development and treatment failures, especially for the taxane class of drugs. This review will focus on taxanes and discuss their mechanisms of resistance and therapeutic strategies to overcome them.

2. Microtubule and taxane structures {#s0010}
====================================

Microtubules are characterized as hollow tubes formed through the heterodimerization of alpha and beta tubulin, resulting in polar protofilaments. They assist in a variety of functions for the cell including structural integrity, transportation and migration, and mitosis as they are a main constituent of mitotic spindles. They are also dynamically active, constantly growing and shrinking in size[@bib20]. The structure of microtubules has been well established. Their outer surface has high alpha helix expression as well as high expression of the C-terminal helices H11 and H12. On the other hand, the inner surface of the microtubules is characterized by long loops[@bib21]. Cryoelectron microscopy has further shown that PXL binds behind the M-loop in the beta-tubulin and interacts with adjacent beta-tubulin H1-S2 loops ([Fig. 1](#f0005){ref-type="fig"})[@bib22]. More recently, taxanes have been implicated in promoting microtubule assembly through creating a short helix in the M-loop, possibly reducing strain and allowing for an easier transition from the curved unbound tubulin to the straight protofilament dimers[@bib23].Figure 1Paclitaxel bound to the active site on *β*I-tubulin (left) and *β*III-tubulin (right). The yellow lines indicate hydrogen bonding between PXL and *β*-tubulin (Gly370 and Thr276). Other key amino acids which potentially interact with PXL are included. Of note, His229 and Phe272 are residues of *π*--*π* interactions. Residues 241 and 277 are mutated in *β*III-tubulin from cysteine and serine to serine and alanine, respectively.Fig. 1

First identified in the early 1970s, PXL is a natural plant substance which binds to microtubules with high affinity (*K*~app~ = 0.87 μmol/L)[@bib24], [@bib25]. Its structure ([Fig. 2](#f0010){ref-type="fig"}, left) contains a baccatin (the molecule which acts as PXL\'s precursor) core, a side chain at the C13 position, and three prominent functional groups: a benzyl amide at the C3′ position, a hydroxyl at C7, and an acetyloxy at C10[@bib26]. As previously mentioned, two other taxanes, DXL and CXL, have been developed since PXL\'s discovery. While possessing the same backbone, the functional groups of these two molecules differ compared to PXL. DXL ([Fig. 2](#f0010){ref-type="fig"}, center) features a *t*-butyl carbamate functionality and a hydroxyl at C3′ and C10, respectively, while CXL ([Fig. 2](#f0010){ref-type="fig"}, right) contains methoxy groups at C7 and C10. The slight variation in structure affects not only binding to the microtubule active site, but efflux pumps as well. Most notably, CXL is not a strong substrate for P-glycoprotein (P-gp)[@bib7], [@bib27].Figure 22D structures of paclitaxel, docetaxel, and cabazitaxel.Fig. 2

3. Mechanisms of taxane resistance and strategies to overcome this resistance {#s0015}
=============================================================================

3.1. Microtubules {#s0020}
-----------------

### 3.1.1. Microtubule mutations contribute to taxane resistance {#s0025}

The active binding site of taxanes to microtubules has been the subject of extensive research in the attempt to elucidate the cause of taxane resistance. Mutations in *β*I-tubulin have been associated with resistance to PXL in other forms of cancer including ovarian cancer[@bib28]. Specifically, different amino acid residues appear to change in the mutated forms of resistance cell lines. The M40 isotype of *β*I-tubulin expresses valine and threonine at residue locations *β*270 and *β*364 instead of phenylalanine and alanine respectively[@bib28]. A mutation of the *β*270 site to isoleucine has also been shown to occur in a prostate cancer DXL resistant cell line, further corroborating the importance of this amino acid site for taxane resistance[@bib29]. Others have shown that a leucine cluster (*β*215, *β*217, *β*228) in the most common form of *β*I-tubulin may change to a variety of other amino acids resulting in PXL resistance[@bib30]. It is not entirely clear whether these mutations result in weaker PXL binding to the active site, or reduction in the subsequent over stabilization of the microtubules, although structural analysis of PXL binding to microtubules indicates valine (*β*:Val23), leucine (*β*:Leu217 and 219), alanine (*β*:Ala233), and arginine (*β*:Arg278 and 282) all play important roles[@bib22], [@bib31].

Increased expression of *β*III-tubulin has also been associated with taxane resistance[@bib8], [@bib32]. One study conducted by Terry et al.[@bib33] examined *β*III-tubulin expression both *in vivo* and *in vitro*. Clinically, only seven samples out of 74 samples (4%) tested positive for *β*III-tubulin if the patient had not been treated with any hormonal therapy. However, 24 out of 40 samples (60%) from patients chronically treated with hormonal therapy tested positive for *β*III-tubulin. Similar results were observed *in vitro* as androgen insensitive cell lines (PC3 and DU145) expressed *β*III-tubulin but androgen-sensitive cells (LNCaP) did not. It was also shown that *β*III-tubulin is more highly expressed in a PXL resistant prostate cancer cell line compared to the parental sensitive cells[@bib34]. Additionally, DXL resistance in multiple cancer types including breast cancer, lung cancer, and prostate cancer has been linked to *β*III-tubulin expression[@bib35], [@bib36], [@bib37], [@bib38]. CXL has also shown to be less effective in high expressing *β*III-tubulin cell lines, indicating *β*III-tubulin is a key factor in all of taxane resistance[@bib39]. Key amino acid changes in *β*III-tubulin around the binding site of PXL are Ser241 and Ala277, compared with Cys241 and Ser277 in *β*I-tubulin[@bib40]. Hypoxia has been identified as a potential cause of increased expression, but evidence as to why *β*III-tubulin is so highly expressed in CRPC is still a mystery. Further studies to identify the underlying mechanisms of this change may be beneficial to patients. A potent inhibitor of this mechanism used in conjunction with taxane therapy may very well prevent development of resistance.

### 3.1.2. Cabazitaxel and other tubulin inhibitors can overcome resistance to PXL and DXL {#s0030}

Both DXL and CXL\'s initial improved efficacy in PXL resistant cell lines and CXLs improved efficacy in DXL resistant cell lines may very well be attributed to variation in structure between the three molecules. Dynamic simulations from Churchill and colleagues[@bib41] of the three drugs binding to microtubules have given insight into the slight variations which very well cause these differences. Both DXL and PXL exhibit relatively rigid structure binding, with emphasis on *π*--*π* interactions within the M-loop and hydrogen bonding. *β*:His229 and *β*:Phe272 seem to constituent the active sites contribution to the *π*--*π* interactions, while aspartate and arginine are essential for the hydrogen interactions. DXL did display slightly better interactions, especially for hydrogen bonding, most likely because of the hydroxyl additions. On the other hand, CXL seems to form a more collapsed form, completely unlike PXL and DXL. This indicates weaker interactions all around and thus most likely weaker binding to the active site.

Another method that has been popular in attempting to overcome the mutations to the taxane binding site is targeting one of two different sites to inhibit tubulin: the colchicine active site or the vinca alkaloid active site. Vinca alkaloids (VA), while successful in treating other forms of cancer, have exhibited mixed results in treating prostate cancer and currently no VA is FDA approved for this disease[@bib42], [@bib43], [@bib44]. No molecule targeting the colchicine active site has been approved for treatment of any cancer, although two prodrug variations of combretastatin A-4, which disrupts angiogenesis, advanced to clinical trials for the treatment of solid tumors[@bib45], [@bib46], [@bib47]. Both VA and colchicine binding agents are known to destabilize tubulin dynamics, although most of the exact mechanisms of action are still unknown.

3.2. Cancer stem cells {#s0035}
----------------------

### 3.2.1. CSC development leads to taxane resistance {#s0040}

The development of cancer stem cells (CSC) has been associated with various forms of cancer for some time with CSCs being identified in prostate cancer in 2005[@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56]. CD133, CD44, ALDH, and *α*1*β*2 integrin have all been associated biomarkers for stemness in prostate cancer and new evidence suggests resistance to taxane therapy in prostate cancer is at least partially derived from the formation of cells with some or all of these markers[@bib50], [@bib57], [@bib58], [@bib59]. While taxanes are effective at causing cell arrest, not every cell actually dies when its G2/M-phase is disrupted. One study showed that some survive and become a new subset of multinucleated polyploids (MP) which have recently been shown to express CD44 and express resistance to DXL[@bib60]. CD133 has also been associated with taxane resistance in both melanoma and prostate cancer and is quite often highly expressed along with CD44 in prostate cancer[@bib61], [@bib62], [@bib63]. As mentioned, ALDH and *α*1*β*2 integrin are also common markers. However, it remains to be seen whether they correspond to taxane resistance. Studies further examining the impact of taxane therapy on these crucial biomarkers could elucidate their importance. Current research has focused on both preventing CSC development and using CSC targeting molecules in conjunction with taxanes.

### 3.2.2. Preventing CSC development {#s0045}

A new taxoid, SBT-1214, has shown potential anti CSC effects, reducing expression of several stem cell related transcription factors including c-Myc and SOX2, as well as increasing expression of pro-apoptotic proteins p53 and p21 in prostate cancer[@bib64], [@bib65]. In a CSC enriched cell line, PPT2, SBT-1214 suppresses cell growth better than PXL in concentration ranging from 10 nmol/L to 10 μmol/L[@bib65]. Additionally, a novel nanoemulsion formulation of this compound has displayed enhanced pharmacokinetic properties and improved tumor suppression (IC~50~ of \~ 6 nmol/L) in the same cell line compared to both SBT-1214 and Abraxane[@bib66].

Reduction in microRNA miR-34a has also been associated with CSC development and its expression is reduced in CD44+ prostate cancer cells. Upregulation of miR-34a has displayed repressive qualities and both on its own and in combination with PXL[@bib67], [@bib68]. Studies have previously shown that p53 down regulates CD44 expression and the miR-34a pathway is a likely mechanism for this regulation[@bib69]. A small molecule, rubone, has been especially effective at increasing iR-34a expression, although knockdown of p53 significantly reduces efficacy in hepatocellular carcinoma cells[@bib70], [@bib71]. However, a micellar delivery of PXL and rubone increases miR-34a regardless of p53 expression in prostate cancer cell lines[@bib68]. This indicates multiple pathways are responsible for miR-34a up and down regulation in prostate cancer lines and rubone has an effect on at least two of these pathways ([Fig. 3](#f0015){ref-type="fig"}). It could be a potentially useful molecule clinically, since p53 is often absent in cancer cells. The Wnt signaling pathway has also been associated with abnormal CD44 expression through binding of *β*-catenin-TCF1/LEF1 to CD44\'s gene promoter[@bib72]. LGK974, a Wnt inhibitor, is currently undergoing clinical testing and could possibly be tested further in combination with DXL to combat prostate cancer. Additionally, napabucasin, a STAT3 inhibitor currently undergoing clinical trials, has shown the ability to kill prostate cancer stem cells[@bib73]. It is being tested in combination with Abraxane for a variety of other cancers and could potentially be used in combination with DXL for prostate cancer treatment.Figure 3Rubone and the p53 pathway. Rubone can upregulate p53 directly, leading to a decrease in stem cell qualities in cancer cells. The combination of PXL and rubone has shown to be effective in upregulating miR-34a regardless of p53 expression, through another unknown pathway.Fig. 3

These novel potential treatments back the hypothesis that CSCs are a key problem in the fight against prostate cancer progression. However, while CSCs may explain how prostate cells develop resistance to therapy, the exact mechanism of the resistance is still unknown. It is most likely the cause of a variety of mutations which vary in different cell lines *in vitro* and even within a single patient clinically, highlighting the heterogeneity of the disease[@bib74].

3.3. Efflux transporters {#s0050}
------------------------

### 3.3.1. Efflux transporter upregulation precipitate taxane resistance {#s0055}

The Multidrug Resistance (MDR) family of efflux transporters is known to be heavily involved in resistance to various forms of chemotherapy. Increased P-gp expression, certain genetic variants of P-gp, as well as ABCC4 expression have been linked to increased DXL resistance in prostate cancer, although interestingly do not seem to affect the pharmacokinetics of the molecule[@bib75], [@bib76]. Additionally, it has been shown that ABCB5 transfected HEK293 cells exhibit higher resistance (2--3 folds) to PXL and DXL and ABCB5 ATPase activity increases in the presence of DXL[@bib77]. This resistance and activity may be reduced *via* ABCB5 targeted siRNA. Some cell lines which either do not express or overexpress these transporters still develop resistance, indicating this cannot be the only mechanism for developing taxane resistance[@bib34]. CXL has shown significantly decreased affinity for P-gp and can even cross the blood brain barrier which heavily expresses efflux transporters[@bib78]. This mechanism likely contributes to its increased effectiveness in cell lines resistant to other taxanes, indicating avoiding major efflux transporters could be key in preventing resistance to taxanes[@bib78].

### 3.3.2. Resensitizing cells to taxane therapy via efflux inhibition {#s0060}

Recently, anti-androgens have been studied as possible inhibitors of the most important efflux transporters ([Fig. 4](#f0020){ref-type="fig"}). Both P-gp and ABCC4 respond to anti-androgen therapy. Bicalutamide and enzalutamide seem to reduce P-gp activity, leading to sensitivity to DXL once again[@bib4]. Bicalutamide also reduces ABCC4 activity and this is associated with a decrease in ABCC4 mRNA expression as well[@bib79]. However, the mechanism for how anti-androgen therapy may resensitize cells to taxanes is still unclear and may be a direction for future studies. Other inhibitors of P-gp have also been developed and studied in combination with taxane therapy. Verapamil, a known P-gp inhibitor has exhibited synergistic effects with PXL, resulting in a nearly 10-fold decrease in IC~50~ in a PXL resistant breast cancer cell line[@bib80]. Quinine heterodimers and derivatives of coumarin have also shown to improve efficacy of PXL through P-gp inhibition, leading researchers to believe this could be a key to treating taxane resistant prostate cancer[@bib81], [@bib82]. Abraxane, an FDA approved nanoformulation of PXL, is known to escape elimination from P-gp[@bib83]. This has sparked research into other formulations which could possibly do the same, especially those containing DXL. Cellax, a PEGylated carboxymethylcellulose conjugate of DXL, is one example of such a formulation[@bib84]. Binding to albumin in plasma and being internalized *via* an albumin and SPARC complex, Cellax shows improved tumor distribution and sustained concentrations compared to DXL *in vivo*[@bib85]. The formulation\'s slow release prevents cancer cells from upregulating P-gp expression, indicating maximum tumor concentration of taxanes may be an important factor in the development of resistance[@bib86]. Variations of Cellax including those with CXL and podophyllotoxin, a microtubule destabilizer, have also been tested with success and the CXL conjugate showed potential to negate bone loss in treating bone metastatic prostate cancer[@bib27], [@bib87]. Other formulation attempts have used pH, lysosomes, and PLGA among others to achieve superior efficacy *in vivo*[@bib88], [@bib89], [@bib90].Figure 4Efflux transporters and taxanes. DXL (pink) is a major substrate of P-gp, but bicaltuamide (blue) can reverse this sensitivity and sustain efficacy. CXL (orange) is not a P-gp substrate and is effective in many DXL resistant cancers.Fig. 4

3.4. Reactivation of the androgen receptor pathway can reduce taxane efficacy {#s0065}
-----------------------------------------------------------------------------

Androgens, most importantly testosterone and its more active derivative dihydrotestosterone (DHT), are essential for the growth and proliferation of prostate cancer as they are known to stimulate proliferation as well as inhibit apoptosis of these cells[@bib91], [@bib92]. This is the reasoning behind using ADT as the frontline therapy for prostate cancer. However, all three currently approved taxanes have shown to inhibit AR nuclear translocation and/or AR expression too[@bib9], [@bib93], [@bib94]. Evidence indicates that microtubules play an important role in AR translocation, so hyperstabilzation caused by the taxanes is the most likely cause of this inhibition[@bib95]. Specifically, the androgen receptor, bound to both androgen and its microtubule binding site, is expressed in high concentrations in the cytoplasm post PXL administration[@bib95]. Much like after ADT, however, resistance to this therapy develops, indicating the cells have found a way to foster androgen translocation and biosynthesis. This has been further supported by a recent study in which enzalutamide resistant cells also displayed cross resistance to DXL[@bib96]. It is worth noting that, in the same study, CXL did not exhibit this cross resistance in terms of overall proliferation, although AR translocation was still restored to relatively normal levels.

Dehydoepiandrosterone (DHEA) is a native adrenal androgen and its sulfonated form (DHEA-SO~4~) has been implicated in an alternative pathway for prostate cancer proliferation in the presence of ADT[@bib5], [@bib97]. DHEA can be converted to DHT and it is often found in excess in circulation. This pathway depends on the presence of organic anion transporting polypeptides (OATPs) which uptake the molecules into the cell. The expression of these transporters is controlled by the gene expression of the solute carrier organic anion (SLCO) family and these have been shown to be markedly increased in prostate cancer cells[@bib98]. However, this does not account for the impact of taxanes on the ability of DHT to translocate to the nucleus. Studies focusing on this in androgen independent cell lines could give insight into how prostate cancer may exhibit cross resistance to both DXL and enzalutamide, but not CXL.

Enzalutamide and abiraterone have been approved to treat CRPC with proposed mechanisms of inhibiting AR function and are used often in clinics either in conjunction with taxanes or pre/post taxane treatment. As previously mentioned, a recent study conducted by Zhu et al.[@bib4] has implicated enzalutamide in inhibiting P-gp efflux activity in a dose dependent manner, which in turn helped facilitate greater efficacy when used in combination with DXL. In the resistant cell lines, the IC~50~ of DXL decreased from 50 to 7 nmol/L when used in combination with 40 μmol/L of enzalutamide and recorded 60% inhibition of P-gp. However, resistance can develop to these treatments as well. It is also very difficult for doctors to decide the order and/or combination in which various chemotherapies should be given, as there is evidence to suggest both synergy and inhibition in various cases[@bib7], [@bib99]. It is clear that androgens are needed for prostate cancer to proliferate and continued research and development of drugs which hinder this pathway could prove vital for effective treatment.

3.5. PI3K/AKT {#s0070}
-------------

### 3.5.1. Upregulation of PI3K/AKT signaling contributes to taxane resistance {#s0075}

The phosphoinositide 3-kinase (PI3K)/AKT pathway regulates multiple cellular functions through important signaling inductions and increased activation of this pathway has been shown to be a key component in cancer proliferation. In more aggressive prostate cancers, phosphorylated AKT (pAKT) is upregulated, most likely due to the inactivation of the *PTEN* gene[@bib100]. pAKT\'s involvement in the cell cycle as well as its relation to the AR pathway are of particular interest here. It promotes transition to the M-phase through inactivation of WEE1 (a known cdk1 inhibitor) which could promote sensitivity to taxane treatment[@bib101]. Another study has correlated ADT and taxane therapy with upregulation of pAKT indicating this pathway may be an important mechanism for the cell to either reactivate the androgen pathway or reduce its dependence on it[@bib102]. In support of this hypothesis, AKT has also been directly linked to AR signaling in multiple studies[@bib103], [@bib104], [@bib105] ([Fig. 5](#f0025){ref-type="fig"}).Figure 5The relationship between AR translocation and the AKT signaling pathway. Taxanes can directly inhibit AR, but translocation can also be upregulated by increasing pAKT downstream signaling, possibly inducing resistance.Fig. 5

### 3.5.2. Targeting the PI3K/AKT pathway {#s0080}

Treatments targeting this pathway in cancer have been of extensive interest and a few have advanced to various stages of clinical trials. Generally, treatments aim to inhibit one of three important targets in the pathway: PI3K, AKT, or mTOR. PI3K inhibitors have shown limited clinical efficacy, although isoform specific inhibitors, which target only one type of p110 isoform (p110*α*), have shown effectiveness in other cancers while also reducing side effects[@bib106], [@bib107]. These specific inhibitors are yet to be tested in prostate cancer, and there is some concern that most prostate cancers exhibit the other p110 isoform (p110*β*) instead of the one targeted by these drugs[@bib108]. Two different types of AKT inhibitors have shown various degrees of efficacy. Allosteric inhibitors displayed evidence of increased apoptosis and decreased cell proliferation in prostate cancers *in vitro* but no improved benefit from the current standard of care in clinical trials[@bib109], [@bib110]. On the other hand, some AKT ATP site inhibitors have shown greater antitumor effects *in vivo* compared to the allosteric inhibitors and a couple of these molecules are currently being tested in clinical trials in combination with AR inhibitors[@bib111]. Similarly, allosteric mTOR inhibitors have been relatively ineffective in clinical trials[@bib112], [@bib113], [@bib114], but ATP site inhibitors of these compound types seem to prevent tumor growth[@bib115]. One particularly interesting molecule, MLN0128, has shown good potency against prostate cancer mouse models, and is thought to act by targeting the 4EBP1/eIF4E axis and effecting translation of critical mRNA effect the invasive qualities of prostate cancer, PC-3 cells in particular[@bib115]. Other mTOR inhibitors which do not target this axis and are not as effective in combination with taxane therapy. Last but not least, some molecules have been developed to target both the ATP active sites on p110 isoforms and on mTOR, which would inhibit most, if not all signaling from this pathway[@bib116], [@bib117]. Early clinical trials have demonstrated the effectiveness of these molecules in solid tumors and potency in metastatic CRPC is being tested in combination with abiraterone[@bib118].

Based on these data, blocking the ATP active binding sites seem to be a useful method for treating various forms of cancer, although clinical efficacy, side effects, and possible drug--drug interactions are still to be determined. In terms of prostate cancer, the data are much more unclear and treatment with these molecules would most likely need to be in combination with other targeted therapies as well. One AKT inhibitor (MK-2206) improved the efficacy of PXL in two ovarian cancer cell lines, SKOV3 (expresses active AKT) and ES2 (no active AKT), leading to increased apoptosis and IC~50~ reductions of approximately 80% and 55% in the two cell lines respectively[@bib119]. This provides a basis for further research into the combination of AKT inhibitors in combination with taxane therapy for CRPC treatment.

3.6. Mitotic kinase mutations most likely do not contribute to taxane resistance {#s0085}
--------------------------------------------------------------------------------

Based on the knowledge that taxanes are believed to interrupt the M-phase of the cell cycle, there have been efforts to directly target mitotic kinases, rather than microtubules in order to overcome the resistance to taxanes. It is hypothesized that similar efficacy could be produced with a reduction in side effects as well[@bib120], [@bib121]. The three major kinase targets have been Aurora A and B and Polo-like kinase (PLK1). Aurora A and B have principal roles in spindle formation and PLK1 is involved in cytokinesis, bipolar spindle formation, and a positive feedback loop of CDK1[@bib122], [@bib123], [@bib124], [@bib125], [@bib126] ([Fig. 6](#f0030){ref-type="fig"}). *In vitro*, where cells often double at very rapid paces, this strategy proved to be extremely effective. However, clinically these molecules did not exhibit this same effect, barely outperforming a placebo in a couple cases[@bib127], [@bib128]. The reasoning for this is believed to be that, *in vivo*, cells spend significantly less time in the M-phase[@bib129], [@bib130], [@bib131]. Therefore directly targeting mitotic kinases will lead to a less effective therapeutic outcome. This is further supported by evidence which suggests taxanes inhibit cell function through multiple other mechanisms (such as inhibiting the AR pathway as discussed earlier)[@bib132]. While showing initial promise, it seems that mitotic kinases are a dead-end for treating most types of cancer including prostate cancer and resistance is not likely to be related to mitotic kinase mutations. Future studies should focus on other areas of resistance.Figure 6Critical protein pathways involved in cell cycle transition from G2 to M-phase. Cyclin B binds to CDK1, initiating the complexes translocation to the nucleus. Multiple positive and negative feedback loops namely, from CDC25, Wee1, and APC/C^cdc20^ tightly regulate CDK1.Fig. 6

3.7. Other novel treatments to overcome resistance {#s0090}
--------------------------------------------------

Statins have traditionally been used to lower cholesterol for treating cardiovascular disease. However, there is growing evidence that some forms of CRPC use cholesterol to biosynthesize androgen for use, just as with the DHEA pathway discussed earlier[@bib133], [@bib134], [@bib135]. Thus, statins could possess a useful mechanism to prevent the reuptake of androgen post initial ADT. *In vitro* experiments have displayed tumor suppression through both inhibition of androgen synthesize as well as AKT inhibition, with simvastatin exhibiting the strongest antitumor effects[@bib136]. The potential for AKT inhibition means these compounds or possible future derivatives could be useful in combination with DXL or CXL to reduce resistance. While toxicity and is not a major concern considering statins are already FDA approved, more experiments need to be conducted to determine efficacy and possible drug--drug interactions *in vivo* in combination with taxanes.

Novel drug delivery mechanisms have also been subject to extensive research in hopes of improving the bioavailability and reducing systemic toxicity. The nanoemulsion formulation of the taxane SBT-1214 has already been discussed and this is just one example of these efforts. A recent publication from Souchek et al.[@bib137] showed the synergy between DXL and nanoparticles containing the weight loss drug orlistat which inhibits fatty acid synthase, an enzyme over expressed in many cancer types. Orlistat prevents the synthesis of phosphatidylcholine from C-choline, therefore reducing its incorporation in lipids. It is not known how orlistat works in synergy with taxanes, but one hypothesis is that it also improves microtubule stabilization, leading to further hyper stabilization and the nanoparticle delivery system improves bioavailability[@bib137]. Corroborating this theory, Yang and colleagues[@bib138] provided evidence of orlistat binding to *β*-tubulin, although at what site the binding occurs and how this may affect taxane binding is still unknown. One other novel nano-formulation gaining attention is the use of polymeric micelles. These are spherical structures which contain a hydrophobic core surrounded by hydrophilic polymers, commonly polyethylene glycol (PEG). The hydrophobic core is excellent for maintaining the stability of hydrophobic drugs such as taxanes, while the outer hydrophilic molecules enhance the aqueous solubility[@bib139]. One last novel delivery system worth mentioning is a surgically implantable device, which uses magnets to deliver drugs at a specific rate *in vivo*. In a mouse model, DXL was efficiently delivered to the tumor and provided similar efficacy to IV administered DXL, with a mice losing significantly less weight[@bib140]. While a device of this type would probably prove difficult to use clinically, the study once again highlights the importance of increasing the bioavailability of a drug around the tumor site in order to reduce resistance development.

4. Conclusions {#s0095}
==============

Taxanes are still currently the 1st line treatment for CRPC, but they may not solely behave in the manner initially thought, as mounting evidence would suggest. Thus development of resistance is most likely not a function of just one or two mechanisms ([Table 1](#t0005){ref-type="table"}). For years, efflux pumps, P-gp in particular, have been associated with taxane resistance, along with resistance to other chemotherapeutic molecules. While upregulation of these proteins certainly play an integral role in resistance in most cell types, it cannot be the only mechanism. The new evidence supporting the common stem-cell like qualities of prostate cancer cells corroborate this hypothesis. The taxane binding site on microtubules is consistently mutated in resistant cell lines, probably reducing taxane affinity for the active site. The AR pathway seems to be the central link between many forms of inhibition, with both taxanes and AKT inhibitors showing effects on this pathway, in addition to the already approved abiraterone and enzalutamide. However, as previously mentioned, CXL still exhibits significant tumor suppression which is independent of the AR pathway, indicating yet another possible mechanism of resistance. Direct inhibition of the AKT pathway has shown potential in clinical trials and may be effective contributors to combination therapy. The tight regulation of the cell cycle has so far shown to be impervious to specific protein inhibitors such as mitotic kinases, possibly due to the minimal time cells *in vivo* spend in M-phase. Novel formulations and delivery methods of drugs which increase bioavailability may circumvent taxane resistance. Patients may benefit from experiments conducted on the pathways outlined in this paper.Table 1Overview of the major resistance mechanisms to taxane therapy and the strategies to improve therapy.Table 1Resistance mechanismPotential strategy to overcome resistanceMutations to the microtubule binding site and increased expression of *β*III-tubulin[@bib8], [@bib28], [@bib30], [@bib32]Development of other microtubule binding agents, which do not bind the same active site or bind to the mutated forms with high affinity[@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47]Development of cancer stem cells[@bib50], [@bib60]Targeting miR-34a and known stem cell transcription factors such as SOX2 and c-Myc[@bib64], [@bib65], [@bib66], [@bib67], [@bib68], [@bib70], [@bib71]Efflux transporter upregulation[@bib75], [@bib76], [@bib77]Inhibiting efflux transporter activity or development of molecules which do not bind to highly expressed transporters[@bib4], [@bib79], [@bib83]Androgen receptor pathway reactivation[@bib5], [@bib96], [@bib97]Anti-androgen therapy given in combination with taxanes[@bib4], [@bib7]PI3K/AKT signal upregulation[@bib100], [@bib102], [@bib103], [@bib104], [@bib105]Direct inhibition of pathway signaling through PI3K, AKT and mTOR inhibitors[@bib106], [@bib107], [@bib108], [@bib109], [@bib110], [@bib111], [@bib112], [@bib113], [@bib114], [@bib115], [@bib116], [@bib117]

5. Future directions {#s0100}
====================

Further investigation of all novel microtubule binding molecules, especially vinca alkaloids and colchicine binding agents, may help elucidate the most likely mechanism of action for these compounds. Understanding whether these molecules deliver similar effects to taxanes may help determine their usefulness. It is possible that binding to different active sites on microtubules may induce different downstream effects, besides that of G2/M-phase disruption. If so this may open new therapeutic opportunities for these compounds. Furthermore, preventing the development of stem cells is also an interesting point of study. This inhibition would possibly correlate to slower mutations times for cancer cells, leaving them more vulnerable to taxane therapy. Studies conducted on this topic may want to focus on the signaling pathways or mRNA involved and potential targets of inhibition. MicroRNA miR-34a, SOX2, and c-Myc have been identified as potential targets for further study. While AKT inhibitors have already been studied extensively in cancer treatment, the AKT pathway has become increasingly more important in prostate cancer growth and future studies should focus on the magnitude of its impact on cell cycle and androgen translocation. Finding a targetable pathway which disrupts cell cycle regulation in addition to taxanes could prove to be an extremely efficient combination therapy. Additionally, any inhibition of the androgen receptor and its subsequent translocation is crucial for halting the progression of the vast majority of prostate cancers. There may very likely be multiple pathways for AR upregulation. Lastly, novel delivery methods have gained popularity in drug development and continued research into this field could provide a unique method for reducing resistance. Studies testing all these agents on a variety of different prostate cancer cell lines, notably PC3, DU145, LNCaP, and their respective taxane resistant forms, may also give better indication to the possible biomarkers for the various subpopulations which have been known to develop in patients. It is imperative to understand the difference between these cell lines. This will provide crucial knowledge about how prostate cancer cells adapt when confronted with various perturbations allowing for better prediction of future resistance development and ensuing treatment.
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